In acute kidney injury, what are the recommended heparin choices, dosing, and monitoring for venous thromboembolism prophylaxis and therapeutic anticoagulation?

Heparin in Acute Kidney Injury

In patients with acute kidney injury requiring anticoagulation, unfractionated heparin (UFH) is the preferred agent over low-molecular-weight heparin (LMWH) when creatinine clearance is <30 mL/min, due to LMWH's renal elimination and risk of accumulation. 1, 2

VTE Prophylaxis in AKI

Agent Selection by Renal Function

For severe renal impairment (CrCl <30 mL/min):

• Use unfractionated heparin 5,000 units subcutaneously every 8 hours 3, 4
• LMWH should be avoided due to renal clearance and accumulation risk 3, 5
• If LMWH must be used, dose-adjust based on anti-Xa levels 1

For moderate renal impairment (CrCl 30-50 mL/min):

• Either UFH or reduced-dose LMWH with anti-Xa monitoring can be considered
• Dalteparin 5,000 units daily or enoxaparin with dose reduction 3

Dosing Regimen

• Standard prophylaxis: UFH 5,000 units subcutaneously every 8 hours 4
• Every 12-hour dosing is less effective and should be avoided 2, 6
• Continue until patient is fully ambulatory or hospital discharge 4

Therapeutic Anticoagulation in AKI

For Treatment of Established VTE

Intravenous UFH is the preferred initial approach:

• Loading dose: 80 units/kg IV bolus 6, 4
• Maintenance: 18 units/kg/hour continuous infusion 6, 4
• Target aPTT 1.5-2.5 times control (corresponding to anti-Xa 0.3-0.7 IU/mL) 6, 4

Subcutaneous UFH alternative (when IV access limited):

• Initial: 333 units/kg subcutaneous, then 250 units/kg every 12 hours 5, 7
• Fixed-dose unmonitored regimen: 17,500-20,000 units (~220-250 units/kg) every 12 hours has been used successfully in ESRD 7

Monitoring Strategy

Laboratory monitoring is critical in AKI:

• Baseline: aPTT, INR, platelet count, creatinine 4
• During IV infusion: aPTT every 4 hours initially, then at appropriate intervals 4
• During subcutaneous therapy: Check aPTT 4-6 hours after injection 4
• Platelet monitoring: Every 2-3 days from day 4-14 to screen for HIT 5
• Consider anti-Xa monitoring (target 0.3-0.7 IU/mL) as it may be more reliable than aPTT in critically ill patients 8

Dose Adjustments

The FDA label provides clear guidance 4:

• Adjust based on aPTT results using weight-based nomograms
• If aPTT <35 seconds (1.2× control): Give 80 units/kg bolus, increase infusion by 4 units/kg/hour
• If aPTT 35-45 seconds: Give 40 units/kg bolus, increase by 2 units/kg/hour
• If aPTT 71-90 seconds: Decrease by 2 units/kg/hour
• If aPTT >90 seconds: Hold infusion 1 hour, decrease by 3 units/kg/hour

Special Considerations in AKI

Continuous Renal Replacement Therapy (CRRT)

For anticoagulation during CRRT:

• Regional citrate anticoagulation is superior to systemic heparin for safety, efficacy, and filter longevity 9, 10
• If heparin used: 25-30 units/kg bolus, then 1,500-2,000 units/hour infusion 4
• Citrate had longer filter life (46 vs 32 hours), fewer discontinuations (8% vs 33%), and lower costs 9

Critical Illness with AKI

In critically ill patients:

• LMWH preferred over UFH when renal function permits (CrCl >30 mL/min) 11, 12
• For severe renal insufficiency: Use UFH or reduced-dose dalteparin 12
• Anti-Xa monitoring should be considered when using LMWH in renal impairment 12

Heparin-Induced Thrombocytopenia (HIT) in AKI

If HIT suspected or confirmed:

• Immediately discontinue all heparin 13
• For severe renal impairment (CrCl <30 mL/min): Use argatroban exclusively 13
• Initial argatroban dose: 1 mcg/kg/min (reduce to 0.5 mcg/kg/min in hepatic impairment) 13
• Danaparoid is NOT recommended in severe renal failure 13
• Fondaparinux may be used but requires caution with renal dosing 13

Common Pitfalls

1. Using LMWH in severe renal impairment without anti-Xa monitoring risks accumulation and bleeding
2. Every 12-hour UFH prophylaxis is less effective than every 8-hour dosing 2, 6
3. Failing to monitor platelets for HIT, which has higher incidence with UFH (up to 5%) 5
4. Relying solely on aPTT in critically ill patients—anti-Xa may be more accurate 8
5. Continuing heparin when HIT suspected—switch immediately to argatroban in renal failure 13

Transition to Oral Anticoagulation

When converting to warfarin:

• Continue full-dose heparin for minimum 5 days AND until INR ≥2.0 for 24 hours 14, 4
• Start warfarin on day 1 of heparin therapy 3
• Target INR 2.0-3.0 3

For DOACs:

• Stop IV heparin immediately after first DOAC dose 4
• For subcutaneous heparin: Give DOAC 0-2 hours before next scheduled heparin dose 4